Jonathan Piazza compensation by year
ARS Pharmaceuticals Summary Compensation Table · all 2 fiscal years held| Component | FY2020 | FY2021 |
|---|---|---|
| Salary | $62,664 | $425,000 |
| Bonus | $100,000 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $5,909,383 | $0 |
| Non-equity incentive | $32,226 | $187,000 |
| Pension and deferred compensation | $0 | $0 |
| All other | $105,000 | $0 |
| Total | $6,209,273 | $612,000 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARS Pharmaceuticals, Inc. DEF 14A filed April 28, 2022, accession 0001193125-22-127830, and prior-year filings.
How this page was built: the ARS Pharmaceuticals, Inc. filed document, accession 0001193125-22-127830. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 56,048 | — | $21.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ARS Pharmaceuticals, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
ARS Pharmaceuticals’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Laura Shawver | Chief Executive Officer | $821,500 |
| Valerie Odegard | President and Chief Scientific Officer | $633,600 |
| Jonathan Piazza · this page | Chief Financial Officer | $612,000 |
The full ARS Pharmaceuticals compensation record
free company briefThis page is one person within ARS Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ARS Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARS Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.